Miguel F Herrera1,2, Eduardo García-García3,4, Juan F Arellano-Ramos5, Miguel Agustín Madero4, Jorge Antonio Aldrete-Velasco6, Juan Antonio López Corvalá7. 1. INCMNSZ: Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán/National Institute of Medical Sciences and Nutrition Salvador Zubiran, Mexico City, Mexico. miguelfherrera@gmail.com. 2. CMCOEM: Colegio Mexicano de Cirugía para la Obesidad y Enfermedades Metabólicas/Mexican College for the Surgery of Obesity and Metabolic Disorders, Mexico, Mexico. miguelfherrera@gmail.com. 3. INCMNSZ: Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán/National Institute of Medical Sciences and Nutrition Salvador Zubiran, Mexico City, Mexico. 4. SMNE: Sociedad Mexicana de Nutrición y Endocrinología/Mexican Society of Endocrinology and Nutrition, Mexico, Mexico. 5. CMCOEM: Colegio Mexicano de Cirugía para la Obesidad y Enfermedades Metabólicas/Mexican College for the Surgery of Obesity and Metabolic Disorders, Mexico, Mexico. 6. CMIM: Colegio de Medicina Interna de México/Mexican College of Internal Medicine, Mexico, Mexico. 7. IFSO: International Federation for the Surgery of Obesity and Metabolic Disorders, Mexico, Mexico.
Abstract
INTRODUCTION: Metabolic surgery (MS) can be a useful therapeutic strategy in patients with type 2 diabetes (DM2) and obesity. OBJECTIVE: To define the place of MS within DM2 treatment in Mexico. METHODS: A committee of experts consisting of internists and surgeons representing the leading Mexican associations involved in the field was created. Each one responded to a specific question regarding mechanisms involved in controlling DM2, surgical procedures, and the indications and contraindications for MS. This document was prepared based on the presentation and discussion of such answers. RESULTS: Obesity through insulin resistance, incretins, bile salts, and intestinal microbiota plays a determining role in the appearance of DM2. MS improves glucose homeostasis by reducing weight and intake, increasing incretins, and modifying bile salts and microbiota. MS leads to remission of DM2 and reduces cardiovascular risk factors in well-selected cases. We recommend MS as a therapeutic option in DM2 and grade III obesity regardless of metabolic control and grade II and grade I obesity with poor glycemic control. MS could be considered an option in grade II obesity with good metabolic control in the presence of associated comorbidities. Gastric bypass presents the most favorable risk-benefit profile. CONCLUSIONS: Current evidence endorses the inclusion of MS in the algorithm for treatment of DM2 and obesity. The therapeutic approach must be multidisciplinary at experienced centers.
INTRODUCTION: Metabolic surgery (MS) can be a useful therapeutic strategy in patients with type 2 diabetes (DM2) and obesity. OBJECTIVE: To define the place of MS within DM2 treatment in Mexico. METHODS: A committee of experts consisting of internists and surgeons representing the leading Mexican associations involved in the field was created. Each one responded to a specific question regarding mechanisms involved in controlling DM2, surgical procedures, and the indications and contraindications for MS. This document was prepared based on the presentation and discussion of such answers. RESULTS:Obesity through insulin resistance, incretins, bile salts, and intestinal microbiota plays a determining role in the appearance of DM2. MS improves glucose homeostasis by reducing weight and intake, increasing incretins, and modifying bile salts and microbiota. MS leads to remission of DM2 and reduces cardiovascular risk factors in well-selected cases. We recommend MS as a therapeutic option in DM2 and grade III obesity regardless of metabolic control and grade II and grade I obesity with poor glycemic control. MS could be considered an option in grade II obesity with good metabolic control in the presence of associated comorbidities. Gastric bypass presents the most favorable risk-benefit profile. CONCLUSIONS: Current evidence endorses the inclusion of MS in the algorithm for treatment of DM2 and obesity. The therapeutic approach must be multidisciplinary at experienced centers.
Authors: C Dirksen; N B Jørgensen; K N Bojsen-Møller; S H Jacobsen; D L Hansen; D Worm; J J Holst; S Madsbad Journal: Diabetologia Date: 2012-04-27 Impact factor: 10.122
Authors: Anne Vrieze; Els Van Nood; Frits Holleman; Jarkko Salojärvi; Ruud S Kootte; Joep F W M Bartelsman; Geesje M Dallinga-Thie; Mariette T Ackermans; Mireille J Serlie; Raish Oozeer; Muriel Derrien; Anne Druesne; Johan E T Van Hylckama Vlieg; Vincent W Bloks; Albert K Groen; Hans G H J Heilig; Erwin G Zoetendal; Erik S Stroes; Willem M de Vos; Joost B L Hoekstra; Max Nieuwdorp Journal: Gastroenterology Date: 2012-06-20 Impact factor: 22.682
Authors: Laurent Biertho; Stéfane Lebel; Simon Marceau; Frédéric-Simon Hould; François Julien; Simon Biron Journal: Surg Clin North Am Date: 2016-08 Impact factor: 2.741
Authors: G Nosso; E Griffo; M Cotugno; G Saldalamacchia; R Lupoli; G Pacini; G Riccardi; L Angrisani; B Capaldo Journal: Horm Metab Res Date: 2016-01-20 Impact factor: 2.936
Authors: Philip R Schauer; Deepak L Bhatt; John P Kirwan; Kathy Wolski; Stacy A Brethauer; Sankar D Navaneethan; Ali Aminian; Claire E Pothier; Esther S H Kim; Steven E Nissen; Sangeeta R Kashyap Journal: N Engl J Med Date: 2014-03-31 Impact factor: 91.245
Authors: John B Buse; Sonia Caprio; William T Cefalu; Antonio Ceriello; Stefano Del Prato; Silvio E Inzucchi; Sue McLaughlin; Gordon L Phillips; R Paul Robertson; Francesco Rubino; Richard Kahn; M Sue Kirkman Journal: Diabetes Care Date: 2009-11 Impact factor: 19.112
Authors: Francesco Rubino; David M Nathan; Robert H Eckel; Philip R Schauer; K George M M Alberti; Paul Z Zimmet; Stefano Del Prato; Linong Ji; Shaukat M Sadikot; William H Herman; Stephanie A Amiel; Lee M Kaplan; Gaspar Taroncher-Oldenburg; David E Cummings Journal: Diabetes Care Date: 2016-06 Impact factor: 19.112